DKK192.90
0.47% day before yesterday
Copenhagen, Dec 20, 04:59 pm CET
ISIN
DK0015998017
Symbol
BAVA
Sector
Industry

Bavarian Nordic Stock price

DKK192.90
-0.15 0.08% 1M
+36.30 23.18% 6M
+15.45 8.71% YTD
+22.70 13.34% 1Y
-69.40 26.46% 3Y
+25.70 15.37% 5Y
-5.10 2.58% 10Y
Copenhagen, Closing price Fri, Dec 20 2024
+0.90 0.47%
ISIN
DK0015998017
Symbol
BAVA
Sector
Industry

Key metrics

Market capitalization DKK15.17b
Enterprise Value DKK13.41b
P/E (TTM) P/E ratio 13.28
EV/FCF (TTM) EV/FCF 8.39
EV/Sales (TTM) EV/Sales 2.21
P/S ratio (TTM) P/S ratio 2.50
P/B ratio (TTM) P/B ratio 1.42
Revenue growth (TTM) Revenue growth 3.03%
Revenue (TTM) Revenue DKK6.08b
EBIT (operating result TTM) EBIT DKK1.15b
Free Cash Flow (TTM) Free Cash Flow DKK1.60b
Cash position DKK1.87b
EPS (TTM) EPS DKK14.53
P/E forward 17.71
P/S forward 2.82
EV/Sales forward 2.49
Show more

Is Bavarian Nordic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Bavarian Nordic Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Bavarian Nordic forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Bavarian Nordic forecast:

Buy
100%

Financial data from Bavarian Nordic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
6,077 6,077
3% 3%
100%
- Direct Costs 2,890 2,890
47% 47%
48%
3,186 3,186
19% 19%
52%
- Selling and Administrative Expenses 320 320
2% 2%
5%
- Research and Development Expense 1,105 1,105
52% 52%
18%
1,762 1,762
35% 35%
29%
- Depreciation and Amortization 611 611
21% 21%
10%
EBIT (Operating Income) EBIT 1,150 1,150
45% 45%
19%
Net Profit 1,119 1,119
55% 55%
18%

In millions DKK.

Don't miss a Thing! We will send you all news about Bavarian Nordic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Head office Denmark
CEO Paul Chaplin
Employees 1,379
Founded 1992
Website www.bavarian-nordic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today